

LYNX THERAPEUTICS INC

Form 8-K

May 22, 2003

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D. C. 20549**

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 22, 2003

Date of Filing: May 22, 2003

**Lynx Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**0-22570**

(Commission File No.)

**94-3161073**

(IRS Employer Identification No.)

**25861 Industrial Blvd.**

**Hayward, California 94545**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(510) 670-9300**

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required FD Disclosures

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

SIGNATURE

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events and Required FD Disclosure**

On May 22, 2003, Lynx Therapeutics, Inc. issued a press release announcing its transfer to the Nasdaq SmallCap Market. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 7. Financial Statements, *Pro Forma* Financial Information and Exhibits**

**(c) Exhibits**

99.1 Press release entitled Lynx Announces Transfer to the Nasdaq SmallCap Market, dated May 22, 2003.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**LYNX THERAPEUTICS, INC.**

Dated: May 22, 2003

By: /s/ Edward C. Albini

---

Edward C. Albini  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

**Table of Contents**

**INDEX TO EXHIBITS**

99.1 Press release entitled Lynx Announces Transfer to the Nasdaq SmallCap Market, dated May 22, 2003.